Cagrilintide

Cagrilintide is a long-acting amylin analog studied for its role in satiety signaling. Its mechanism is distinct from the incretin pathway targeted by GLP-1 receptor agonists, and it is frequently researched alongside those compounds. Published work has described its development as a long-acting amylin analogue and its evaluation in clinical trials for weight management in adults with overweight or obesity, including combination studies with semaglutide.

Research investigates cagrilintide for activity at amylin and calcitonin receptors. These receptors are studied for their influence on gastric emptying and on the signaling that registers fullness. Because the amylin pathway is separate from the GLP-1 pathway, cagrilintide is often examined in combination research, where its mechanism is considered complementary to, rather than overlapping with, incretin agonists such as semaglutide.

Research has included a phase 1b trial of cagrilintide given concomitantly with semaglutide 2.4 mg, a dose-finding phase 2 trial of once-weekly cagrilintide for weight management, and a phase 2 trial of co-administered cagrilintide 2.4 mg and semaglutide 2.4 mg in type 2 diabetes. Phase 3 trials have evaluated coadministered cagrilintide and semaglutide in adults with overweight or obesity, with and without type 2 diabetes.

Safety and tolerability were assessed as study endpoints across the phase 1b, phase 2 and phase 3 trials of cagrilintide, both alone and combined with semaglutide. Specific adverse event rates are not summarized on this page, and readers seeking detail should consult the published trial reports. Long-term human safety data for cagrilintide used on its own are more limited than data for the combination with semaglutide.

Research protocols have used 250 to 2,000 mcg per administration, three times per week in the morning under fasted conditions, stepping up from 250 mcg to 2 mg by week 13. A reported clinical cycle involved a 16-week titration, and an alternative model used 8 weeks on and 8 weeks off at 500 mcg once weekly. Each CoreX order ships with a protocol guide.